Yorktown Management & Research Co Inc Takes Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Yorktown Management & Research Co Inc purchased a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,600 shares of the biotechnology company's stock, valued at approximately $559,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Retirement Systems of Alabama grew its position in shares of Sarepta Therapeutics by 0.3% in the 4th quarter. Retirement Systems of Alabama now owns 116,145 shares of the biotechnology company's stock valued at $14,122,000 after purchasing an additional 299 shares during the period. abrdn plc raised its holdings in shares of Sarepta Therapeutics by 6.2% during the fourth quarter. abrdn plc now owns 457,695 shares of the biotechnology company's stock worth $55,294,000 after acquiring an additional 26,597 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in Sarepta Therapeutics by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 20,254 shares of the biotechnology company's stock valued at $2,463,000 after acquiring an additional 1,912 shares in the last quarter. Sivik Global Healthcare LLC acquired a new position in Sarepta Therapeutics in the 4th quarter worth $1,216,000. Finally, Swedbank AB bought a new position in Sarepta Therapeutics during the 4th quarter worth about $16,706,000. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Stock Down 0.3 %

SRPT stock traded down $0.29 during mid-day trading on Friday, reaching $111.82. 881,445 shares of the company traded hands, compared to its average volume of 847,020. The firm's 50 day moving average price is $121.12 and its 200 day moving average price is $126.11. Sarepta Therapeutics, Inc. has a fifty-two week low of $102.15 and a fifty-two week high of $173.25. The stock has a market cap of $10.68 billion, a price-to-earnings ratio of 89.46 and a beta of 0.75. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

Wall Street Analyst Weigh In

Several analysts recently issued reports on SRPT shares. StockNews.com lowered Sarepta Therapeutics from a "buy" rating to a "hold" rating in a report on Wednesday, November 20th. Evercore ISI reduced their price objective on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating for the company in a research report on Thursday, November 7th. Piper Sandler cut their target price on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating for the company in a research note on Wednesday, November 27th. Needham & Company LLC restated a "buy" rating and set a $202.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, January 27th. Finally, Robert W. Baird lowered their price target on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating on the stock in a research report on Thursday, November 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $178.71.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the sale, the director now owns 5,880 shares of the company's stock, valued at approximately $738,234. The trade was a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the transaction, the director now directly owns 22,840 shares of the company's stock, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.70% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.